Accessibility Menu
Bristol Myers Squibb logo

Bristol Myers Squibb

(NYSE) BMY

Current Price$60.71
Market Cap$124.04BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1968)+20,371%
5 Year+11%
1 Year+32%
1 Month+11%
Bristol Myers Squibb last closing stock price
MetricPriceDate
Last closeUSD 60.742026-07-17
Bristol Myers Squibb stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+5.49%USD 57.582026-07-10
1 month+11.12%USD 54.662026-06-17
3 month+2.09%USD 59.502026-04-17
Year to date+16.41%USD 52.182025-12-31
1 year+32.45%USD 45.862025-07-17
3 year+12.82%USD 53.842023-07-18
5 year+10.76%USD 54.842021-07-16
Since inception+20,371.09%USD 0.301968-01-02

Bristol Myers Squibb Financials at a Glance

Market Cap

$124.04BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$48.48B

Net Income (TTM)

$7.28B

EPS (TTM)

$3.56

P/E Ratio

17.05

Dividend

$2.51

Beta (Volatility)

0.29 (Low)

Price

$60.71

Volume

495,051

Open

$60.61

Previous Close

$60.71

Daily Range

$60.47 - $62.28

52-Week Range

$42.52 - $62.89

Estimated Earnings Date

Jul 30, 2026

BMY News

A biotech lab technician using multiple pipettes to load blood samples into test tubes.

5 Best Biotech Stocks for 2026 and How to Invest

Keith SpeightsJul 17, 2026
office_building_commercial_real_estate

5 Best Commercial Real Estate Stocks for 2026

Kristi WaterworthJul 16, 2026
Woman question marks in background

Is Bristol Myers Squibb's 4.3% Dividend Yield Safe? Here's What Investors Need to Know.

Keith SpeightsJul 6, 2026
TMF-Pills-Blue-StockVStock.png

Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

Erin KennedyJul 1, 2026
TMF-Pills-Purple-StockVStock.png

Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

Sara AppinoJun 26, 2026
Time to Buy Stopwatch

3 Reasons to Buy Bristol Myers Squibb Stock

Justin PopeJun 22, 2026
Pharmacist talking to patient

3 Dividend Stocks to Hold for the Long Haul

Prosper Junior BakinyJun 16, 2026
Woman using gloves to hold up and inspect a red pill.

Biotech vs. Pharma: What's the Difference?

Keith SpeightsJun 14, 2026
Page 1

BMY: Motley Fool Moneyball Superscore

66

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Bristol Myers Squibb

Bristol-Myers Squibb makes medicines for cancer, heart, and immune diseases. Its drugs help patients manage serious health conditions. Products like Eliquis are used for stroke prevention and Opdivo is used for cancer treatment.

Pill Bottles and Beyond: What Bristol-Myers Squibb Sells

  • Oncology and Hematology: Cancer and blood disorder drugs, including Opdivo, Revlimid, and Pomalyst, for hospitals and clinics.
  • Cardiovascular (Eliquis, about 28% of revenue in 2024): Eliquis helps prevent strokes and blood clots in patients with heart rhythm disorders.
  • Immunology: Orencia and Zeposia treat autoimmune diseases like rheumatoid arthritis and multiple sclerosis for adults.
  • Cell Therapies: Breyanzi and Abecma are advanced treatments for certain blood cancers, used when other options fail.
  • Neuroscience: Cobenfy, launched in 2024, addresses schizophrenia symptoms for adult patients.

Growth Spurts: How Bristol-Myers Squibb Got Bigger

  • Acquired Karuna (neuroscience), RayzeBio (radiopharmaceuticals), and Mirati (oncology) in 2024.
  • Launched new drugs in 2024, including Cobenfy for schizophrenia and Krazati for certain cancers.
  • Expanded manufacturing and research sites in the US, India, and Europe in 2024.
  • Formed strategic alliances, such as with Pfizer for Eliquis and SystImmune for new cancer therapies.

What Makes Bristol-Myers Squibb Stand Out

The company distributes medicines globally, reaching hospitals, pharmacies, and clinics. It invests heavily in research, focusing on new treatments for hard-to-treat diseases. Strategic acquisitions and partnerships help Bristol-Myers Squibb diversify its product pipeline and expand into new markets.

Five Things You Need to Know

  • Total revenue was $48.3 billion in 2024, up 7% from 2023.
  • US sales made up 71% of revenue in 2024; international sales were 27%.
  • R&D expenses rose 20% to $11.2 billion in 2024.
  • Net loss was $8.95 billion in 2024, mainly due to acquisition costs.

Bottom Line

Bristol-Myers Squibb has evolved through acquisitions, new drug launches, and global expansion. Its focus on research and diverse products helps it adapt in a changing healthcare market.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

32,500

CEO

Christopher S. Boerner, PhD, MBA

Website

www.bms.com

Headquarters

Princeton, NJ 08543, US

BMY Financials

Key Financial Metrics (TTM)

Gross Margin

68.75%

Operating Margin

25.67%

Net Income Margin

15.01%

Return on Equity

39.05%

Return on Capital

19.35%

Return on Assets

8.41%

Earnings Yield

5.87%

Dividend Yield

4.13%

Payout Ratio

69.69%

Stock Overview

Market Cap

$124.04BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.04B

Volume

495.05K

Avg. Volume

11.72M

Financials (TTM)

Gross Profit

$33.33B

Operating Income

$12.45B

EBITDA

$13.75B

Operating Cash Flow

$13.31B

Capital Expenditure

-$1.40B

Free Cash Flow

$11.91B

Cash & ST Invst.

$10.49B

Total Debt

$44.46B

Bristol Myers Squibb Performance Analysis

Bristol Myers Squibb annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 46,159,000,000-0.5%
20232023-12-31USD 45,006,000,000-2.5%
20242024-12-31USD 48,300,000,0007.3%
20252025-12-31USD 48,194,000,000-0.2%
Bristol Myers Squibb sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-309.5%
Q32025-09-30-0.4%
Q42025-12-312.3%
Q12026-03-31-8.1%
Bristol Myers Squibb annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 2.95-5.4%
20232023-12-31USD 3.8631.0%
20242024-12-31USD -4.41N/A
20252025-12-31USD 3.46N/A
Bristol Myers Squibb sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-46.7%
Q32025-09-3068.8%
Q42025-12-31-50.9%
Q12026-03-31147.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$11.49B

+2.6%

Gross Profit

$8.07B

+9.9%

Gross Margin

70.22%

N/A

Market Cap

$124.04BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.82M

N/A

Employees

32,500

N/A

Net Income

$2.68B

+9.0%

EBITDA

$3.68B

-17.9%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$10.49B

-11.0%

Total Debt

$44.46B

-13.2%

Accounts Receivable

$12.08B

-17.2%

Inventory

$2.76B

+3.4%

Long Term Debt

$42.15B

-11.3%

Short Term Debt

$2.31B

-38.1%

Return on Assets

8.41%

N/A

Return on Invested Capital

18.49%

N/A

Free Cash Flow

$757.00M

-55.3%

Operating Cash Flow

$1.10B

-43.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
VRTXVertex Pharmaceuticals Incorporated
$485.65-0.08%
CVSCVS Health Corp.
$107.47+0.91%
SNYSanofi
$44.66+1.02%
PFEPfizer Inc.
$25.05-0.36%

Trending Stocks

Symbol / CompanyPricePrice Chg
AALAmerican Airlines Group
$14.98-0.04%
INTCIntel
$95.04-0.02%
NOKNokia
$10.12-0.03%
PATHUiPath
$12.15+0.01%

Questions About BMY

What is the current price of Bristol Myers Squibb?

Bristol Myers Squibb is trading at $60.71 per share.

What is the 52-week range for Bristol Myers Squibb?

Over the past 52 weeks, Bristol Myers Squibb has traded between $42.52 and $62.89.

How much debt does Bristol Myers Squibb have?

As of the most recent reporting period, Bristol Myers Squibb reported total debt of $46.43B.

How much cash does Bristol Myers Squibb have on hand?

Bristol Myers Squibb reported $9.57B in cash and cash equivalents in its most recent financial results.

What is Bristol Myers Squibb’s dividend yield?

Bristol Myers Squibb currently has a dividend yield of 4.13%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services